



A



B

Compound(unit)	IC50		IC50 ratio
	CAPAN1	CAPAN1 BRCA2/CIN	
Mitomycin C (nm)	1463	2677	0.55

C



D

Compound(unit)	IC50		IC50 ratio
	DLD1 BRCA2 <sup>KO</sup>	DLD1	
Mitomycin C (nm)	098	1604	0.06

Figure S3. BRCA2 deficiency enhances the sensitivity of cancer cells towards mitomycin C. SYBR green proliferation assay of BRCA2 deficient CAPAN1 and the respective syngenic BRCA2/CIN cell line complemented to express wild-type BRCA2 (A, B) and homozygous BRCA2 knockout colorectal cancer cell line DLD1 termed DLD1 BRCA2<sup>KO</sup> vs. wild-type DLD1 cells (C, D) after 6 days of treatment with olaparib or TRAIL in increasing concentrations. All experiments were performed at least in duplicates with error bars representing SEM from independent experiments. B, D: IC50 values obtained for each compound tested and their ratio, defined as IC50 in the context of BRCA2 deficiency divided by IC50 in the context of BRCA2 proficiency.